1.62
-0.04(-2.41%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.65 |
| Day High | 1.65 |
| Day Low | 1.62 |
| 52-Week High | 17.19 |
| 52-Week Low | 0.61 |
| Volume | 440,408 |
| Average Volume | 1.3M |
| Market Cap | 262.35M |
| PE | -1.03 |
| EPS | -1.57 |
| Moving Average 50 Days | 1.63 |
| Moving Average 200 Days | 2.51 |
| Change | -0.04 |
If you invested $1000 in Neumora Therapeutics, Inc. Common Stock (NMRA) since IPO date, it would be worth $99.69 as of September 13, 2025 at a share price of $1.62. Whereas If you bought $1000 worth of Neumora Therapeutics, Inc. Common Stock (NMRA) shares 1 year ago, it would be worth $134.66 as of September 13, 2025 at a share price of $1.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neumora Therapeutics to Participate in Upcoming Conferences in September
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
GlobeNewswire Inc.
Jul 23, 2025 11:00 AM GMT
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage program
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
GlobeNewswire Inc.
Jul 09, 2025 11:00 AM GMT
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIR